Resveratrol was the most hyped longevity compound of the 2000s — a red wine molecule that activated sirtuins and extended lifespan in yeast. The human trial evidence tells a considerably more complicated story.
In 2003, David Sinclair's laboratory published a paper in Nature showing that resveratrol activated Sir2 — the yeast sirtuin — and extended replicative lifespan by up to 70%. This was the beginning of a decade of extraordinary scientific and commercial excitement.
The mechanistic hypothesis was elegant: resveratrol mimics caloric restriction by activating SIRT1, the mammalian homolog of Sir2, which in turn activates downstream longevity pathways including AMPK and PGC-1α. A 2006 paper in Nature showed that resveratrol extended lifespan in obese mice on a high-fat diet. GlaxoSmithKline acquired Sirtris Pharmaceuticals — a company built on the sirtuin hypothesis — for $720 million in 2008.
The popular press ran headlines about red wine and immortality. Resveratrol supplements became a multi-hundred-million-dollar industry. The question was always whether any of this would translate to humans.
The first major problem is pharmacokinetic. Oral resveratrol has approximately 1% bioavailability in humans — it is rapidly metabolized by intestinal and hepatic first-pass enzymes into sulfate and glucuronide conjugates that are largely inactive. Achieving the plasma concentrations used in cell culture experiments requires gram-level doses that are difficult to tolerate and expensive.
The second major problem came from the NIA Interventions Testing Program. The ITP, which uses rigorous multi-site protocols to test longevity interventions in mice, tested resveratrol and found no lifespan extension in normal-weight mice — only in the obese mouse model. The 2006 Nature paper result may have been confounded by the metabolic disease state of the animals.
GlaxoSmithKline halted its entire SIRT1 activator program in 2013 after safety signals — kidney toxicity and cardiac issues — emerged in clinical trials of SRT2104, a more potent SIRT1 activator developed from the resveratrol program.
More than 30 human trials of resveratrol have been published. The results are inconsistent. Some small trials have shown benefits on inflammatory markers, insulin sensitivity, and blood pressure. Others have shown null results or, in one notable case, reduced benefits of exercise in older men.
Resveratrol is not a fraud — the underlying biology of sirtuin activation is real and continues to be studied. But its evidence profile as an oral supplement for human longevity is weak. The bioavailability problem limits plasma exposure, the ITP found no lifespan extension in healthy mice, the GSK program was halted for safety, and the human trials are inconsistent and underpowered.
The evidence tier is Insufficient. This does not mean the compound is harmful or that sirtuin biology is unimportant — it means the current evidence for oral resveratrol supplementation does not meet the threshold for clinical recommendation. Pterostilbene, a related compound with better bioavailability, has a modestly better evidence profile and is tracked separately.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.